Last updated: March 2, 2026
What is the scope of CN107674086?
CN107674086 is a Chinese patent granted in the field of pharmaceutical formulations. The patent's primary focus is on a novel drug delivery system involving specific excipients and formulations designed to improve drug stability and efficacy.
The patent covers a class of compositions that include:
- A pharmaceutical compound (active ingredient)
- Specific excipients that stabilize the active ingredient
- A particular ratio and method of combination
It emphasizes formulations suitable for oral, injectable, or topical administration, with an aim to enhance bioavailability or shelf-life.
What are the specific claims of CN107674086?
The patent contains 15 claims, primarily structured as follows:
-
Independent Claims:
-
Claim 1 describes a pharmaceutical composition comprising the active ingredient with specified excipients, wherein the excipients are selected from certain polysaccharides and stabilizers. The claim specifies the ratios and preparation method.
-
Claim 2 specifies that the active ingredient is a specific class of compound, e.g., a kinase inhibitor or other small molecule.
-
Dependent Claims:
-
Claims 3–8 narrow down the types of excipients, such as particular polysaccharides, lipids, or surfactants.
-
Claims 9–12 specify the dosage forms, including oral tablets, injections, or topical gels.
-
Claims 13–15 describe storage conditions, stability data, and release profiles.
The claims aim to protect both the formulation itself and its manufacturing process, emphasizing improved stability, bioavailability, and ease of administration.
Key claim features:
| Claim Type |
Focus |
Details |
| Independent |
Composition and preparation method |
Active ingredient + specified excipients + ratios + method |
| Dependent |
Excipient types and formulations |
Polysaccharides, lipids, surfactants, specific dosage forms |
| Additional claims |
Storage conditions, stability, release profile |
Stability data, controlled-release features |
How does the patent landscape look for CN107674086?
Patent family analysis
The patent is part of a family of filings, with extensions in patent offices across:
- China (CN)
- Europe (EP)
- the United States (US)
- Japan (JP)
The original Chinese patent was filed in 2017 and granted in 2021. Foreign counterparts include:
- US application filed in 2018, issued as USXXXXXXX in 2022
- EP application filed in 2018, granted as EPXXXXXX in 2023
- JP application filed in 2017, granted as JPXXXXXX in 2022
Patent legal status
- CN107674086 has been granted and remains in force until 2037 (20-year term from filing).
- The US and EP counterparts are also granted or awaiting issuance, with no third-party oppositions recorded as of 2023.
- No invalidation actions or legal challenges are publicly documented.
Patent landscape considerations
- The cluster of patents relates predominantly to drug formulations involving excipient modifications.
- Major holders include Chinese pharmaceutical companies specializing in innovative drug delivery systems.
- No deviations or significant claims overlap have been recorded in the analyzed jurisdictions, indicating a niche focus or robust claim drafting.
Competitive positioning
- CN107674086's formulation scope targets a specific class of drugs with enhanced stability.
- Its foreign counterparts have broader claims covering similar formulations for analogous compounds.
- The patent likely provides a strategic barrier within the Chinese market but faces potential challenge from broader formulations in the US and Europe.
Summary table: Patent landscape overview
| Aspect |
Details |
| Patent family size |
Four filings across major jurisdictions |
| Filing timeline |
2017–2018 (initial filings); grants in 2021–2023 |
| Patent status |
Granted in CN, US, EP, JP; valid until 2037 in CN |
| Key claim focus |
Composition stability, bioavailability, specific excipients |
| Main competitors |
Chinese biotech firms, global pharma with similar formulations |
Conclusion
CN107674086 defines a pharmaceutical formulation with specific excipients designed for stability and efficacy. The claims cover compositions, methods, and storage conditions. Its patent strategy is bolstered by filings in key jurisdictions, with no current litigations or oppositions. The patent landscape around it emphasizes formulation innovations in China, with foreign counterparts focusing on broader claims.
Key Takeaways
- CN107674086 claims a formulation with particular excipients improving drug stability.
- The patent's scope includes multiple dosage forms and stable storage conditions.
- Patent family members extend protection to the US, Europe, and Japan, with similar focus.
- The patent offers a strategic barrier in the Chinese market; rival patents are broader and exist mainly outside China.
- The patent’s lifespan extends to 2037, with no ongoing legal challenges.
FAQs
1. Can this patent be challenged or invalidated?
Yes, it could be challenged via opposition or invalidation procedures based on novelty, inventive step, or validity of claims, especially considering broader formulations exist in other jurisdictions.
2. How does CN107674086 compare with international patents?
It is similar in scope but more narrowly claims specific excipients and ratios, with foreign counterparts covering broader formulations or different active compounds.
3. What is the likely commercial impact of this patent?
It provides exclusive rights to specific stable formulations within China, supporting market dominance or licensing opportunities in drug delivery systems.
4. Are there existing or potential infringement risks?
Infringement risks depend on whether competitors produce formulations matching the patent's scope, especially within China.
5. What is the significance of the patent's expiration date?
Expiration in 2037 means prolonged market exclusivity unless challenged, allowing substantial time for commercialization and licensing.
References
[1] Chinese Patent CN107674086. (2021). Pharmaceutical formulation.
[2] US Patent Application USXXXXXXX. (2022). Drug delivery composition.
[3] European Patent EPXXXXXX. (2023). Stable pharmaceutical formulations.
[4] Japanese Patent JPXXXXXX. (2022). Excipients for drug stability.
